Umbricht, Daniel

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression

eQTLGen, Wray, N. R., 23andMe, the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E. M., Abdellaoui, A., Adams, M. J., et al. (2018) · Nature Genetics

Genetic Associations and EpidemiologyTreatment of Major Depression

Cited by 3,005

Mismatch negativity in schizophrenia: a meta-analysis

Umbricht, D., & Krljes, S. (2005) · Schizophrenia Research

Schizophrenia research and treatmentHallucinations in medical conditions

Cited by 742

Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia

Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012) · Schizophrenia Bulletin

Schizophrenia research and treatmentNeuroscience and Neuropharmacology Research

Cited by 322

Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors

Mullins, N., Kang, J., Campos, A. I., Coleman, J. R. I., Edwards, A. C., Galfalvy, H., Levey, D. F., Lori, A., Shabalin, A., Starnawska, A., et al. (2022) · Biological Psychiatry

Suicide and Self-Harm StudiesGenetic Associations and Epidemiology

Cited by 238

Translating Glutamate: From Pathophysiology to Treatment

Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., et al. (2011) · Science Translational Medicine

Neuroscience and Neuropharmacology ResearchTreatment of Major Depression

Cited by 168

The FDA-NIMH-MATRICS Guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Buchanan, R. W., Keefe, R. S. E., Umbricht, D., Green, M. F., Laughren, T., & Marder, S. R. (2011) · Schizophrenia Bulletin

Schizophrenia research and treatmentStatistical Methods in Clinical Trials

Cited by 154

Integrated analysis of environmental and genetic influences on cord blood DNA methylation in new-borns

Czamara, D., Eraslan, G., Page, C. M., Lahti, J., Lahti-Pulkkinen, M., Hämäläinen, E., Kajantie, E., Laivuori, H., Villa, P. M., Reynolds, R. M., et al. (2019) · Nature Communications

Epigenetics and DNA MethylationBirth, Development, and Health

Cited by 143

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

Bolognani, F., del Valle Rubido, M., Squassante, L., Wandel, C., Derks, M., Murtagh, L., Sevigny, J., Khwaja, O., Umbricht, D., & Fontoura, P. (2019) · Science Translational Medicine

Autism Spectrum Disorder ResearchNeuroendocrine regulation and behavior

Cited by 128

Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target

Goeldner, C., Ballard, T. M., Knoflach, F., Wichmann, J., Gatti, S., & Umbricht, D. (2013) · Neuropharmacology

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 96

Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder

Umbricht, D., Niggli, M., Sanwald-Ducray, P., Deptula, D., Moore, R., Grünbauer, W., Boak, L., & Fontoura, P. (2020) · The Journal of Clinical Psychiatry

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 39